All News

How long would it take you to pack if someone from emergency preparedness were to knock on your door and say you have 24 hours or less to be ready to leave your home with no certainty it might still be livable when you return?

Patients with advanced renal cell carcinoma have new first-line therapy options.

Thousands of men who will be diagnosed with prostate cancer this year alone now have a wealth of new and updated resources to ensure they make the best treatment choices they can.

Precision medicine has prolonged life for many with lung cancer, giving them opportunities to support those who are newly diagnosed.

The power of friendship within the world of metastatic cancer has hit home for this survivor.

$600,000 grant awarded over three years at Boston Children’s Hospital.

A two-time cancer survivor finds cancer worries a little easier to face with time and experience.

Compared with the general population, men and women with type 2 diabetes face greater risk of developing certain cancers, such as colorectal, kidney, liver and more.

We've got a sneak peek at what’s inside Heal®'s spring issue.

While many advances have been made in the treatment landscape of MCL, the need for curative treatment options may be where future research goes.

I have two perspectives as I look at clinical trials: as the patient needing one and as an advocate encouraging patients to enroll in them. But how can I encourage someone to do something that I personally find so frustrating?

With no available diagnostic tests for the detection and/or monitoring of bladder cancer, researchers from the Medical College of Georgia at Augusta University may have two new urine tests that determine the disease’s severity and detect for its recurrence.

Art is a creative outlet that provides health benefits to those affected by cancer. Art therapy is becoming more widely used in the field of medicine as its ability to help people is evidenced.

One expert discusses the significance of newer drugs and the role they play in helping patients with relapsed or refractory disease.

From the first annual Glioblastoma Awareness Day to politics and today’s top performers, here’s what’s making headlines in the cancer space this week.​

We've got a sneak peek at what’s inside CURE®'s lung cancer special issue.

A small molecule drug may help to overcome resistance to Imbruvica in patients with MCL, according to preclinical study findings from The University of Texas MD Anderson Cancer Center.

May is recognized as Bladder Cancer Awareness Month. Know the facts and statistics in order to understand your risk for the disease and take preventative actions to guard your health.

A diagnosis of cancer is completely overwhelming and something most of us are not prepared for. It may be easy to think about giving up before treatment starts. Instead, here are five things that helped me push through.

The Food and Drug Administration has approved the combination use of Venclexta plus Gazyva for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

A recent study showed that postmenopausal women demonstrated a significant reduction in the risk for bladder cancer after quitting smoking, highlighting the need for prevention and cessation programs in older women.

The combination use of Abraxane plus gemcitabine and cisplatin for the treatment of advanced biliary tract cancers prolonged survival, according to phase 2 study findings.

The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted against approving a new drug application for quizartinib for adult patients with relapsed/refractory FLT3-ITD–positive AML.

Sometimes it doesn't pay to make comparisons.

The Food and Drug Administration approved the combination use of Bavencio plus Inlyta for the first-line treatment of patients with advanced renal cell carcinoma.

Carrying chronic illness can be very difficult, but there are ways to navigate the world without being crushed by the weight of what we cannot control.

The FDA’s Oncologic Drugs Advisory Committee voted in favor of the agency approving pexidartinib to treat adult patients with symptomatic tenosynovial giant cell tumor – a rare, benign lesion that can be locally aggressive and often recurring.

Researchers at Baylor College of Medicine found that a particular subgroup of patients with advanced bladder cancer, identified with a computational tool, responded to immunotherapy.